https://orcid.org/0000-0003-1230-0492
Figures & data
Table 1. Characteristics of study participants.
Table 2. Prevalence of IgG (N), IgG (S), and T-cell response (S1 and SNMO) at study start (n = 69).
Figure 1. Magnitude of T-cell response to S1 antigen (SFU/well) [normalised to the positive control (anti-CD3)] and IgG S antibody levels (BAU/mL) at the study end (n = 59).
![Figure 1. Magnitude of T-cell response to S1 antigen (SFU/well) [normalised to the positive control (anti-CD3)] and IgG S antibody levels (BAU/mL) at the study end (n = 59).](/cms/asset/aa72aaa1-2401-461c-b70e-c15a52a4ef97/infd_a_2142662_f0001_c.jpg)
Figure 2. Magnitude of T-cell response to S1 antigen (SFU/well) [normalised to the positive control (anti-CD3)] and days passed since the second vaccine dose (n = 59).
![Figure 2. Magnitude of T-cell response to S1 antigen (SFU/well) [normalised to the positive control (anti-CD3)] and days passed since the second vaccine dose (n = 59).](/cms/asset/6c4ec6d2-53ab-442e-aac5-951212c6cca4/infd_a_2142662_f0002_c.jpg)
Table 3. T-cell response to S1 and SNMO antigens after vaccination for participants with previous COVID-19 (as reported by the participant and/or diagnosed during the study) and participants with no COVID-19.
Supplemental material